U.S. Anesthesia Partners Refutes Federal Trade Commission's Misguided Allegations

Since the approval of the first antibody-drug conjugate (ADC) in 2000, ADCs have become a massive  focus in the oncology sector. This is due to the fact that they are able to combine highly specific targeting with a potent cytotoxic payload to deliver exceptional results.But how have they been so successful where small molecules haven’t? Abzena’s Chief Scientific Officer, Dr Campbell Bunce,  share